Catalyst is a Biotech Stock Ready to Expand

CatalystBargain alternative investing is all about finding the high-potential picks that are ready for expansion. Catalyst Biosciences Inc. (NASDAQ: CBIO) is one that could create significant returns in the coming months. Catalyst develops innovative treatments for serious medical conditions. Its treatments for hemophilia and other life-threatening blood-related disorders use subcutaneous coagulation technology to regulate clotting. Novel treatments in late-stage clinical trials will drive revenue in the coming years.

Analysts are confident that the company’s unique therapeutics, high efficacy, and seamless testing phase will lead to eventual approval for Catalyst’s most promising treatments. The average stock price target of $19 suggests a significant upside for investors who buy at today’s price. With the expected release of the company’s in-trial drugs, analysts predict an even bigger high-end target of $25.

In the most recent full fiscal year, Catalyst reported cash and assets of $96.07 million. The company has the funding to carry it through to the release of its pipeline drugs.

Considering that the stock trades for just over $6.00 today, now could be the perfect time to invest and hold for the expected upside. There’s risk in this pick, but the potential gains make it a quintessential bargain option.

Key Data:

  • 1 Year Price Growth: -1.21%
  • YTD Price Growth: -3.33%
  • 3 Month Price Growth: 21%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.

 

The reports, research and newsletter are based on current and historical market data, as well as publicly available financial data.They are intended to be a starting point for investors. They do not provide every material fact about a company or industry, nor are they recommendations to buy or sell. The writers and the company make no warranties or representations as to the accuracy of these reports.   You should NOT rely solely upon the information or opinions read in the content. Rather, you should use the content as a starting point for doing independent research on the independent analysis and trading methods in the content. The content is impersonal and does not provide individualized advice or recommendations for any specific reader or individual portfolio. By accessing this website you have agreed to our disclaimers and privacy policy.

 

You May Also Like

About the Author: Writocity